The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease
Open accessAbstract
Objectives: The study aimed to develop evidence-based recommendations for the treatment of rapidly progressive interstitial lung disease (RPILD) associated with the anti-Melanoma Differentiation-Associated Gene 5-positive dermatomyositis (DM) syndrome. Methods: The task force comprised an expert panel of specialists in rheumatology, intensive care medicine, pulmonology, immunology, and internal medicine. The study was carried out in two phases: identifying key areas in the management of DM-RPILD syndrome and developing a set of recommendations based on a review of the available scientific evidence. Four specific questions focused on different treatment options were identified. Relevant publications in English, Spanish or French up to April 2018 were searched systematically for each topic using PubMed (MEDLINE), EMBASE, and Cochrane Library (Wiley Online). The experts used evidence obtained from these studies to develop recommendations. Results: A total of 134 studies met eligibility criteria and formed the evidentiary basis for the recommendations regarding immunosuppressive therapy and complementary treatments. Overall, there was general agreement on the initial use of combined immunosuppressive therapy. Combination of high-dose glucocorticoids and calcineurin antagonists with or without cyclophosphamide is the first choice. In the case of calcineurin antagonist contraindication or treatment failure, switching or adding other immunosuppressants may be individualized. Plasmapheresis, polymyxin B hemoperfusion and/or intravenous immunoglobulins may be used as rescue options. ECMO should be considered in life-threatening situations while waiting for a clinical response or as a bridge to lung transplant. Conclusions: Thirteen recommendations regarding the treatment of the anti-MDA5 positive DM-RPILD were developed using research-based evidence and expert opinion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
Courtwright, A. M., El-Chemaly, S., Dellaripa, P. F., & Goldberg, H. J. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.12.013 · Cited by 73
Cited by
Idiopathic inflammatory myopathies
Lundberg, I. E., Fujimoto, M., Vencovsky, J., Aggarwal, R., Holmqvist, M., Christopher-Stine, L., Mammen, A. L., & Miller, F. W. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00321-x · Cited by 703
Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies
Nombel, A., Fabien, N., & Coutant, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773352 · Cited by 262
Metadata
- Authors
- Romero-Bueno, F., Diaz del Campo, P., Trallero-Araguás, E., Ruiz-Rodríguez, J. C., Castellvi, I., Rodriguez-Nieto, M. J., Martínez-Becerra, M. J., Sanchez-Pernaute, O., Pinal-Fernandez, I., Solanich, X., Gono, T., Gonzalez-Gay, M. A., Plana, M. N., & Selva-O'Callaghan, A.
- Venue
- Seminars in Arthritis and Rheumatism
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 50
- Issue
- 4
- Pages
- 776-790
- ISSN
- 0049-0172 (ISSN-L)
- OpenAlex
- W3033556276
- Cited by
- 184
- References
- 2
- FWCI
- 17.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. https://app.cochat.ai/papers/10.1016/j.semarthrit.2020.03.007
- The paper
- Romero-Bueno, F., Diaz del Campo, P., Trallero-Araguás, E., Ruiz-Rodríguez, J. C., Castellvi, I., Rodriguez-Nieto, M. J., Martínez-Becerra, M. J., Sanchez-Pernaute, O., Pinal-Fernandez, I., Solanich, X., Gono, T., Gonzalez-Gay, M. A., Plana, M. N., & Selva-O'Callaghan, A. (2020). Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Seminars in Arthritis and Rheumatism. https://doi.org/10.1016/j.semarthrit.2020.03.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.